National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China.
Eur Radiol. 2022 Feb;32(2):1195-1204. doi: 10.1007/s00330-021-08156-6. Epub 2021 Aug 1.
To compare the treatment success and safety of ultrasound- and MR-guided high-intensity focused ultrasound (HIFU) with surgery for treating symptomatic uterine fibroids.
We searched studies comparing HIFU with surgery for fibroids in different databases from January 2000 to July 2020. The mean difference (MD) or relative risk (RR) with 95% confidence interval (CI) for different outcome parameters was synthesized.
We included 10 studies involving 4450 women. Compared with the surgery group, the decrease in uterine fibroid severity score at 6- and 12-month follow-up was higher in the HIFU group (MD - 4.16, 95% CI - 7.39 to - 0.94, and MD - 2.44, 95% CI - 3.67 to - 1.20, p < 0.05). The increase in quality-of-life (QoL) score at 6- and 12-month follow-up was higher in the HIFU group (MD 2.13, 95% CI 0.86 to 3.14, and MD 2.34, 95% CI 0.82 to 3.85, p < 0.05). The duration of hospital stay and the time to return to work was shorter in the HIFU group (MD - 3.41 days, 95% CI - 5.11 to - 1.70, and MD - 11.61 days, 95% CI - 19.73 to - 3.50, p < 0.05). The incidence of significant complications was lower in the HIFU group (RR 0.33, 95% CI 0.13 to 0.81, p < 0.05). The differences in the outcomes of adverse events, symptom recurrence, re-intervention, and pregnancy were not statistically significant (p > 0.05).
HIFU is superior to surgery in terms of symptomatic relief, improvement in QoL, recovery, and significant complications. However, HIFU showed comparable effects to surgery regarding the incidence of adverse events, symptom recurrence, re-intervention, and pregnancy.
• HIFU ablation is superior to surgery in terms of symptomatic relief, improvement in QoL, recovery, and significant complications. • HIFU has comparable effects to surgery in terms of symptom recurrence rate, re-intervention rate, and pregnancy rate, indicating that HIFU is a promising non-invasive therapy that seems not to raise the risk of recurrence and re-intervention or deteriorate fertility compared to surgical approaches in women with fibroids. • There is still a lack of good-quality comparative data and further randomized studies are necessary to provide sufficient and reliable data, especially on re-intervention rate and pregnancy outcome.
比较超声和磁共振引导高强度聚焦超声(HIFU)与手术治疗有症状子宫肌瘤的治疗成功率和安全性。
我们检索了从 2000 年 1 月至 2020 年 7 月不同数据库中比较 HIFU 与手术治疗子宫肌瘤的研究。不同结局参数的均数差值(MD)或相对风险(RR)采用 95%置信区间(CI)进行综合。
我们纳入了 10 项研究,涉及 4450 名女性。与手术组相比,HIFU 组在 6 个月和 12 个月时的子宫肌瘤严重程度评分下降更高(MD-4.16,95%CI-7.39 至-0.94,MD-2.44,95%CI-3.67 至-1.20,p<0.05)。HIFU 组在 6 个月和 12 个月时的生活质量(QoL)评分升高更高(MD2.13,95%CI0.86 至 3.14,MD2.34,95%CI0.82 至 3.85,p<0.05)。HIFU 组的住院时间和恢复工作时间更短(MD-3.41 天,95%CI-5.11 至-1.70,MD-11.61 天,95%CI-19.73 至-3.50,p<0.05)。HIFU 组严重并发症发生率较低(RR0.33,95%CI0.13 至 0.81,p<0.05)。不良事件、症状复发、再干预和妊娠结局的差异无统计学意义(p>0.05)。
HIFU 在缓解症状、提高 QoL、恢复和严重并发症方面优于手术。然而,在不良事件、症状复发、再干预和妊娠发生率方面,HIFU 与手术的效果相当。
• HIFU 消融在缓解症状、提高生活质量、恢复和严重并发症方面优于手术。• HIFU 在症状复发率、再干预率和妊娠率方面与手术相当,表明 HIFU 是一种有前途的非侵入性治疗方法,与手术方法相比,似乎不会增加肌瘤女性的复发和再干预风险,也不会降低生育能力。• 目前仍缺乏高质量的对照数据,需要进一步的随机研究来提供足够和可靠的数据,特别是在再干预率和妊娠结局方面。